Keystone symposia – Modern Phenotypic Drug Discovery: From Chemical Biology to Therapeutics

Keystone symposia – Modern Phenotypic Drug Discovery: From Chemical Biology to Therapeutics

 

Biognosys is proud to present the highlights of a recent study in which we describe the potentialities of limited proteolysis for proteomics analysis. The oral presentation, “Limited proteolysis as a proteomics tool for target deconvolution and mechanistic insights – a test case,” will be held by our Scientific Director of Discovery Proteomics, Nigel Beaton, on May 25th.

 

Helpdesk

Access our knowledge base with relevant resources and guiding information.

Contact

    Close banner

    Spectronaut® 16

    The Deepest Proteome
    Coverage Available

    New: Spectronaut® 16

    The Deepest Proteome Coverage Available

    learn more